11/10 Taiwan BIO Weekly
2025-11-10 |
| Taiwan BIO Weekly |
| Taiwan Excellence showcases AI surgery innovations and more at MEDICA 2025 6 November, 2025 Taiwan will have a significant presence at MEDICA 2025, with more than 250 companies from the country exhibiting. Among them, the Taiwan Excellence Pavilion (Hall 16, Booth B-13) serves as a central showcase where 15 award winning companies will present 23 MedTech innovations recognised for technological excellence and real world healthcare impact. More... |
| PharmaEssentia to advance five new drugs into clinical trials in 2026, partners with TBMC to enter the cell therapy field 6 November, 2025 PharmaEssentia (TW: 6446) held a shareholder meeting recently where it announced plans to expand new indications for its drug Ropeg and continue developing first-in-class and best-in-class drugs, with five new candidates expected to enter clinical trials next year. In addition, PharmaEssentia has formally partnered with Taiwan Biopharmaceutical Manufacturing Company (TBMC) to enter the cell therapy field. PharmaEssentia is actively expanding Ropeg's new indications, including early-stage primary myelofibrosis or low- to intermediate-risk primary myelofibrosis in a global Phase III trial, which has already enrolled more than 10 patients and is expected to complete enrollment by March next year. The company is also exploring Ropeg for other indications beyond the MPN field, such as cutaneous T-cell lymphoma (CTCL) and chronic myeloid leukemia (CML). More... (in Chinese) |
| At SITC Annual Meeting, HanchorBio's HCB301 protein drug debuts with first data presentation 6 November, 2025 At the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) held November 7-9, 2025, in National Harbor, Maryland, US, anti-cancer drug development company HanchorBio (TW: 7827), will present three new research findings via poster sessions. The first to be featured is the preclinical data for its novel tri-functional fusion protein drug HCB301, followed by clinical data on its broad-spectrum anti-cancer drug HCB101 as a monotherapy and in combination treatments. HanchorBio reported that HCB301's preclinical results demonstrated good safety, synergistic immune activation, and significant tumor control, providing sufficient evidence to support progression into clinical trials. More... (in Chinese) |
| Foxconn partners with Taiwan hospital, care provider to apply healthcare tech 6 November, 2025 Foxconn, Mackay Memorial Hospital, and the Shiang Bao Long-term Care Group have partnered to roll out AI-powered healthcare solutions, including wearable monitoring systems, telemedicine platforms, and muscle-support assistive devices. The collaboration aims to enhance care quality and efficiency in Taiwan's long-term care sector, which faces challenges due to an aging population. Foxconn plans to deploy wearable devices and cloud-based analytics to support caregivers and the elderly, per CNA. More... |
| YD Bio and EG BioMed Expand US Access to OkaiDx, a cfDNA Methylation Blood Test for Post-Treatment Breast Cancer Monitoring Press release 5 November, 2025 YD Bio Limited (NasdaqGM: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced its support for the global commercialization of OkaiDx, a research-use-only (RUO) blood test for post-treatment breast cancer monitoring now available through the Company's affiliate EG Biomed US's CLIA/CAP-certified laboratory in the United States. YD Bio's role is to support commercialization efforts for OkaiDx under the authorization granted to the Company, working alongside EG BioMed to make the assay accessible to research laboratories, academic groups and industry partners conducting surveillance and translational studies. More... |
| Andros Pharmaceuticals completes capital increase, brings in new institutional investors 5 November, 2025 Andros Pharmaceuticals (TW: 6917) has successfully completed a cash capital increase, issuing 10,000,000 new shares at NT$17 each to raise NT$170 million. Supported by existing shareholders and directors--some of whom waived their subscription rights--the fundraising also brought in institutional investors. The proceeds will strengthen working capital and support clinical trials for the company's two lead drug candidates, APC201 and APC101, while accelerating overall drug development and business expansion. More... (in Chinese) |
| Medimaging Integrated Solution officially launches sales in US market 5 November, 2025 Medimaging Integrated Solution (TW: 6796) announced that its FDA-cleared disposable bronchoscope is now officially on sale in the US through Tri-anim Health Services, a subsidiary of Sarnova, a major nationwide distributor specializing in respiratory, anesthesia, and critical care products for hospitals and patient care facilities. More... (in Chinese) |
| Next-Generation Wound Care: Guiding the Body to Heal Itself 4 November, 2025 Researchers at National Taiwan University have discovered how light, electricity, and tiny forces can work together to help wounds heal naturally and leave fewer scars, offering new hope for chronic wound care. More... |
| Bridging Taiwan-US Research and Driving Biotech Innovation! The 2025 TTBA Symposium Kicks Off in Houston! 4 November, 2025 Director General Yvonne Hsiao and Science & Technology Division Director Dr. Pin-Chuan Chen from the Taipei Economic and Cultural Office in Houston were invited to attend the 2025 TTBA Annual Symposium, organized by the Texas Taiwanese Biotechnology Association (TTBA). This two-day event brought together leading scholars and industry experts from Taiwan and the United States to explore key topics in cancer translational research, industrial innovation, and research commercialization, showcasing the vibrant momentum of Taiwan-US collaboration in biotechnology. More... |
| Lin BioScience's subsidiary Belite's new drug poised for UK approval 4 November, 2025 Lin BioScience (TW: 6696) announced that its US subsidiary Belite Bio (NASDAQ: BLTE) has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to submit a conditional marketing authorization (CMA) application for LBS-008, a Phase III therapy for Stargardt disease (STGD1), based on interim results from its DRAGON clinical study. If approved, LBS-008 could become the world's first therapy for this rare eye disorder, boosting Lin BioScience and Belite's stocks, which rose to NT$292.5 and US$105.91, respectively. Founded in 2016, Lin BioScience spun off Belite in 2017. In just eight years Belite has advanced LBS-008 from preclinical studies to Phase III trials and is now pursuing international regulatory submissions. If approved, LBS-008's market potential is estimated at USD billions. More... (in Chinese) |
| Pharmosa Biopharm's long-acting inhaled drug shows promising results 4 November, 2025 New drug developer Pharmosa Biopharm (TW: 6875) held an investor conference recently where it stated that L606, a long-acting inhaled therapy exclusively developed by Pharmosa Biopharm and licensed to US company Liquidia, demonstrated excellent safety and low side effects. Results from the open-label Phase III trial showed that L606 significantly improved daily exercise capacity and quality of life in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Overall, the clinical performance of L606 outperformed existing and pipeline inhaled therapies on the market. More... (in Chinese) |
| Medeon Biodesign, Taiwan Bio Therapeutics, and 3D Global Biotech target US market 3 November, 2025, 2025 Not letting the new drug sector steal the spotlight, the regenerative medicine and innovative medical device fields also delivered good news in October. Medeon Biodesign (TW: 6499), Taiwan Bio Therapeutics (TW: 6892), and 3D Global Biotech (TW: 6808) are all expanding into the US market. Institutional investors note that accelerating multinational clinical collaborations and overseas plant construction has become a clear trend. Medeon Biodesign's Urocross Retrieval Sheath has received US FDA approval, with the main BPH treatment system planned for submission later this year. Taiwan Bio Therapeutics is building a Phoenix, US, manufacturing base while its Treg therapy TRK-001 completes Phase II trials and holds US FDA orphan drug status for kidney transplant rejection. 3D Global Biotech is establishing a San Diego, US, subsidiary and US FDA-compliant cell GMP facility, leveraging Taipei Medical University expertise in a dual-core Taipei-San Diego model, targeting US clinical trials for Alzheimer’s, diabetic nephropathy, and myocardial infarction. More... (in Chinese) |
| ========================================= |
| Taiwan Bio Industry Organization (Taiwan BIO) Tel: +886 2 27836028 Fax: +886 2 27836027 Email: biotaiwan@gmail.com BIO Asia-Taiwan 2026 (15-19 July, 2026) ========================================= Taiwan Bio Industry Organization (Taiwan BIO) Room C229, 2F, Bldg. C, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei, Taiwan (11571) ========================================= |